Work

1238eTiP Phase I/IIa, open-label, dose finding, safety and exploratory trial of THEO-260: A novel oncolytic immunotherapy, by intravenous delivery in patients with high grade serous or endometrioid ovarian cancer

Year: 2025

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.1871

Authors: M. Saggese, P. Roxburgh, D. Cartwright, M. Lythgoe, M. Zameer, M. Bazan Peregrino, R. Ackerman-Johnson, R. Dattani, A. Smith, K. Fisher, D. Apelian, S. Blagden, M. Duffy, J. Krell

Institutions: Theolytics (United Kingdom), Beatson West of Scotland Cancer Centre, Imperial College London, University of Oxford

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415939725

FWCI: 0.392

Cites:

Cited by: 1

Related to: 10